Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
174 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00972335 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | terminated | Phase 2 | 18 | SCRI Development Innovations, LLCOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT00402883 | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer | terminated | Phase 2 | 5 | SCRI Development Innovations, LLCOTHER | 1 | Nov 9, 2021 |
| NCT00297596 | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00193050 | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | completed | Phase 2 | 110 | SCRI Development Innovations, LLCOTHER | 0 | Oct 26, 2021 | clinicaltrials |
| NCT02125084 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 | 38 | SCRI Development Innovations, LLCOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT02436772 | Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC | completed | — | 74 | SCRI Development Innovations, LLCOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | completed | Phase 2 | 9 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02291913 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | completed | Phase 2 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01490866 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01487265 | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01401959 | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | completed | Phase 2 | 127 | SCRI Development Innovations, LLCOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01829113 | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer(Spruce) | completed | Phase 2 | 155 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01626352 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | completed | Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00789581 | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer(TITAN) | completed | Phase 3 | 614 | SCRI Development Innovations, LLCOTHER | 2 | Jul 2, 2017 | clinicaltrials |
| NCT01934894 | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | terminated | Phase 2 | 11 | SCRI Development Innovations, LLCOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01848145 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia | completed | Phase 2 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01844817 | Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer(Rainier) | completed | Phase 2 | 132 | SCRI Development Innovations, LLCOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy | completed | Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00906282 | Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT01749956 | 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer | completed | Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | terminated | Phase 2 | 2 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT00536341 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 64 | SCRI Development Innovations, LLCOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01611857 | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | completed | Phase 1 / Phase 2 | 49 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01527487 | Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer | completed | Phase 2 | 76 | SCRI Development Innovations, LLCOTHER | 1 | Nov 4, 2016 | clinicaltrials |
| NCT01404650 | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00887575 | Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 54 | SCRI Development Innovations, LLCOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT00544817 | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme | completed | Phase 2 | 47 | SCRI Development Innovations, LLCOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT01029730 | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | completed | Phase 2 | 55 | SCRI Development Innovations, LLCOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT00737243 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | completed | Phase 2 | 289 | SCRI Development Innovations, LLCOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00193375 | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01769508 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer | terminated | Phase 2 | 12 | SCRI Development Innovations, LLCOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00193180 | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT01042288 | Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01076504 | A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 81 | SCRI Development Innovations, LLCOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT00609804 | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01522833 | Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer | completed | — | 27 | SCRI Development Innovations, LLCOTHER | 1 | Mar 7, 2016 | clinicaltrials |
| NCT02035124 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT01121939 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | completed | Phase 2 | 43 | SCRI Development Innovations, LLCOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 202 | SCRI Development Innovations, LLCOTHER | 1 | Jan 29, 2016 | clinicaltrials |
| NCT01048099 | Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer | completed | N/A | 283 | SCRI Development Innovations, LLCOTHER | 1 | Jan 29, 2016 | clinicaltrials |
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 0 | Dec 10, 2015 | clinicaltrials |
| NCT00621049 | Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC | completed | Phase 2 | 112 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00632489 | LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | completed | Phase 1 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials